RecruitingPHASE1, PHASE2NCT06735755
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Studying Glycogen storage disease due to glucose-6-phosphatase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beam Therapeutics Inc.
- Intervention
- BEAM-301: Single dose of BEAM-301 administered by IV(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (3)
- Clinical Study Site, Orange, California, United States
- Clinical Study Site, Farmington, Connecticut, United States
- Clinical Study Site, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06735755 on ClinicalTrials.govOther trials for Glycogen storage disease due to glucose-6-phosphatase deficiency
Additional recruiting or active studies for the same condition.
See all trials for Glycogen storage disease due to glucose-6-phosphatase deficiency →